Scientific Programme 2022

Areas of controversy – Topics for APCCC 2022

• Intermediate- and high-risk and locally advanced prostate cancer.
• Prostate-specific antigen (PSA) persistence and biochemical recurrence after definitive treatment.
• Management of side effects caused by hormonal therapy.
• Management of newly diagnosed metastatic hormone- sensitive prostate cancer (mHSPC).
• Management of non-metastatic castration-resistant prostate cancer (nmCRPC).
• Management of metastatic CRPC.
• Oligometastatic and oligoprogressive prostate cancer.